ClinicalTrials.gg
CompletedNCT00480662Updated Aug 14, 2024

A Research Study to Test the Effectiveness of MK0217 in Patients With Paget's Bone Disease (0217-206)(COMPLETED)

A Phase 3 interventional study of alendronate in Paget's Disease of Bone, sponsored by Organon and Co. Completed. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-08-14.

Sponsored by Organon and Co · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Study summary

To test the safety, effectiveness of MK0217 when taken once a week for six months in treating patients with Paget's bone disease.

02

Conditions studied

  • Paget's Disease of Bone

Browse trials for

Keywords

  • Paget's bone disease
03

In context

Osteitis Deformans

21 studies on the registry are indexed under Osteitis Deformans; 1 is open to participants now.

This study's enrollment of 60 is above the median of 52 across 13 interventional studies indexed under Osteitis Deformans.

Browse Osteitis Deformans studies →

Lead sponsor

Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.

Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, ages 18 to 90 years with a diagnosis of Paget's bone disease

Exclusion criteria

Exclusion Criteria:

  • Patient cannot stand or sit upright for at least 30 minutes
  • Patient has difficulty swallowing or problems with digestive system
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
60 participants (actual)

Interventions

  • Duration of Treatment : 6 Months

    Also known as: MK0217

06

What researchers measure

Primary outcomes

  1. Patients will have a decrease of at least 30% in their blood alkaline phosphatase level after 6 months

Secondary outcomes

  1. MK0217 will be safely tolerated

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Hooper M, Faustino A, Reid IR, Hosking D, Gilchrist NL, Selby P, Wu M, Salzmann G, West J, Leung A. Randomized, active-controlled study of once-weekly alendronate 280 mg high dose oral buffered solution for treatment of Paget's disease. Osteoporos Int. 2009 Jan;20(1):141-50. doi: 10.1007/s00198-008-0639-6. Epub 2008 Jun 7. PubMed 18536953 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2001, a primary completion of Oct 2002 and a completion of Oct 2002. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2007
First posted
May 31, 2007
Start
Oct 2001
Primary completionActual
Oct 2002
CompletionActual
Oct 2002
Last update
Aug 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00480662
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
May 31, 2007
Start date
Oct 2001
Primary completion
Oct 2002
Completion
Oct 2002
Last update
Aug 14, 2024

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alendronate

Start the discussion